

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AUSTAR

奧星

Austar Lifesciences Limited

奧星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
DISCLOSEABLE TRANSACTION -
CONSTRUCTION AGREEMENT
FOR THE NEW SONGJIANG FACILITY**

Reference is made to the announcement (“**Announcement**”) of Austar Lifesciences Limited dated 23 October 2020 in relation to the Construction Agreement. Unless the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcement.

This announcement is made to provide supplemental information in relation to the identity of the ultimate beneficial owner of the Contractor.

To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, the Contractor is owned as to approximately 83.58% by 達海控股集團有限公司 (Dahai Holding Group Co., Ltd.*) (“**Dahai Holding**”), approximately 9.79% by 南通四建集團有限公司工會委員會 (Nantong Sijian Construction Group Co., Ltd. Trade Union Committee*), and the remaining approximately 6.62% by 42 individuals each holding not less than 0.046% and not greater than 0.58% of the shareholding. Dahai Holding, a company established in the PRC, is owned as to approximately 46.82% by 南通海融投資管理股份有限公司 (Nantong Hairong Investment Management Co., Ltd.*) (“**Nantong Hairong**”) and the remaining approximately 53.18% by 48 individuals each holding not less than 0.25% and not greater than 8.92% of the shareholding. Nantong Hairong, a company established in the PRC, is owned as to approximately 63.82% by 南通嘉融投資管理有限公司 (Nantong Jiarong Investment Management Co., Ltd.*), a company established in the PRC and wholly owned by Dahai Holding, and the remaining approximately 36.18% by 54 individuals each holding not less than 0.565% and not greater than approximately 2.09% of the shareholding.

As disclosed in the Announcement, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries each of the Contractor and its ultimate beneficial owners is an Independent Third Party.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 30 October 2020

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.

** For identification purpose only*